Stoke Therapeutics STOK 深 沪
已收盘 10-30 16:00:00 美东时间
26.29
-0.060
-0.23%
华盛通- 最 高26.715
- 今 开26.04
- 成交量 185.68万股
- 最 低 25.76
- 昨 收 26.35
- 总市值 16.96亿
- 52周最高 40.22
- 市盈率 静 --
- 换手率 2.88%
- 52周最低 21.81
- 委 比 78.66%
- 总股本 6452.62万
- 历史最高 71.58
- 量 比 1.13
- 振 幅 3.62%
- 历史最低 3.35
- 每 手 1
- 风险率 3.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Stoke Therapeutics收涨1.68%，成交额5288.26万美元
10月27日，Stoke Therapeutics（STOK）收涨1.68%，报25.46美元，成交额5288.26万美元，市值16.43亿美元。 行情数据 ...
10-27 05:32
Stoke Therapeutics收跌1.79%，成交额2133.3万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:35
Stoke Therapeutics Presents Data For STK-002 Supporting Disease-Modifying Potential In Autosomal Dominant Optic Atrophy At AAO 2026 Annual Meeting
–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision loss– –STK-002 represents a novel approach to ADOA by targeting the underlying disease biolo...
10-12 20:07
Stoke Therapeutics appoints new independent board director
Stoke Therapeutics ( ($STOK) ) just unveiled an update. On September 22, 2026, ...
09-26 04:55
Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5–...
09-01 19:31
美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price Target
JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.
08-22 03:06
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
Stoke Therapeutics Charts Path From EMPEROR To Launch
Stoke Therapeutics (($STOK)) has held its Q2 earnings call. Read on for the mai...
08-05 08:58
Stoke Therapeutics Files Prospectus For Up To $200M ATM Stock Offering; Replaces Prior Program After Selling 4.7M Shares For $146.4M In Net Proceeds
Up to $200,000,000 Common Stock We previously entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor, relating to shares of our common stock offered by this prospectus supplement and the accompanying base prospectus. In accordance...
08-04 05:07
